Differential expression of MKP1 is known to influence outcomes in autoimmune diseases (47) and has also been identified as a potential therapeutic target in the management of metabolic disorders, central nervous system disease, cancer, and inflammatory diseases like asthma and sarcoidosis (48). Here, DUSP1 is linked to metabolic disease.